Whitehouse Station
TRENTON, N.J. - Two federal agencies are probing drugmaker Merck & Co.
Drugmaker Merck & Co. on Friday reported a 52 percent drop in second-quarter net income, weighed down by big restructuring charges from buying Schering-Plough Corp., generic competition and other factors.
More News
- Merck partners with South African drugmaker
- Merck: Schering-Plough integration is track
- Merck settles patent dispute on cholesterol drug
- Merck 1Q sales rise but profit fall on charges
- Merck promotes key VP to president
- Analyst: Merck's Vytorin sales will keep dropping
- Merck to pay 38-cent quarterly dividend
- Schering-Plough purchase hikes Merck sales, profit
- Merck to appoint drug safety monitors to end suits
- Merck buys British maker of biotech medicines
- Merck names Tufts dean as chief medical officer
- FDA approves OTC version of heartburn drug Zegerid
- Merck says key Fosamax lawsuit dismissed
- Merck claims win in Texas lawsuit over Vioxx
